Inmune Bio Stock Market Value
| INMB Stock | USD 1.48 0.09 5.73% |
| Symbol | INmune |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. Market participants price INmune higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive INmune Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.17) | Revenue Per Share | Quarterly Revenue Growth 2.571 | Return On Assets | Return On Equity |
INmune Bio's market price often diverges from its book value, the accounting figure shown on INmune's balance sheet. Smart investors calculate INmune Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since INmune Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
INmune Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to INmune Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of INmune Bio.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in INmune Bio on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding INmune Bio or generate 0.0% return on investment in INmune Bio over 90 days. INmune Bio is related to or competes with CEL SCI, Barinthus Biotherapeutics, Aligos Therapeutics, Tempest Therapeutics, OnKure Therapeutics, Skye Bioscience, and X4 Pharmaceuticals. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate i... More
INmune Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure INmune Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess INmune Bio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.59 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 22.66 | |||
| Value At Risk | (7.51) | |||
| Potential Upside | 6.82 |
INmune Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for INmune Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as INmune Bio's standard deviation. In reality, there are many statistical measures that can use INmune Bio historical prices to predict the future INmune Bio's volatility.| Risk Adjusted Performance | 0.0162 | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.50) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0228 |
INmune Bio February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0162 | |||
| Market Risk Adjusted Performance | 0.0328 | |||
| Mean Deviation | 3.58 | |||
| Semi Deviation | 4.32 | |||
| Downside Deviation | 4.59 | |||
| Coefficient Of Variation | 10032.83 | |||
| Standard Deviation | 4.55 | |||
| Variance | 20.72 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.50) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0228 | |||
| Maximum Drawdown | 22.66 | |||
| Value At Risk | (7.51) | |||
| Potential Upside | 6.82 | |||
| Downside Variance | 21.09 | |||
| Semi Variance | 18.63 | |||
| Expected Short fall | (3.99) | |||
| Skewness | 0.0197 | |||
| Kurtosis | 0.1214 |
INmune Bio Backtested Returns
At this point, INmune Bio is very risky. INmune Bio holds Efficiency (Sharpe) Ratio of 0.0364, which attests that the entity had a 0.0364 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for INmune Bio, which you can use to evaluate the volatility of the firm. Please check out INmune Bio's Downside Deviation of 4.59, market risk adjusted performance of 0.0328, and Risk Adjusted Performance of 0.0162 to validate if the risk estimate we provide is consistent with the expected return of 0.17%. INmune Bio has a performance score of 2 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 1.55, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, INmune Bio will likely underperform. INmune Bio right now retains a risk of 4.68%. Please check out INmune Bio downside variance, daily balance of power, and the relationship between the maximum drawdown and skewness , to decide if INmune Bio will be following its current trending patterns.
Auto-correlation | 0.54 |
Modest predictability
INmune Bio has modest predictability. Overlapping area represents the amount of predictability between INmune Bio time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of INmune Bio price movement. The serial correlation of 0.54 indicates that about 54.0% of current INmune Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.54 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:Check out INmune Bio Correlation, INmune Bio Volatility and INmune Bio Performance module to complement your research on INmune Bio. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
INmune Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.